EU regulatory revision: Hype dying down – sense and seriousness can prevail
This article was originally published in Clinica
It’s like a tightrope act for both the devices industry and the Brussels regulators: free market access for innovative, patient outcome-enhancing technology has to be balanced against patient safety. They want the optimum, most usable system, and that is what the European Commission is reaching for as it prepares to table its proposal for the new EU regulatory framework in late September.
You may also be interested in...
Point-of-care/near-patient testing has been “two years away from major breakthrough” for at least two decades, but fast access to data via automation and IT means that progress might change at last. How the tests are paid for remains an issue. The future of POC was the theme of an investor discussion at the first DxPx conference, held during the Medica 2019 event in Germany.
For many, the EU MDR is coming too fast, yet several of its crucial elements are not yet in place. Germany’s liberal FDP MPs say the national government needs to make a stand and address a European issue that will impact German patients. In a motion to parliament, the MPs propose fast-tracking for innovative products and measures to keep orphan devices in circulation.
The Queen’s speech last month signaled new legislation for medical devices after the UK leaves the umbrella of EU legislation, following the December election result. The bill is expected to enter its second reading in March 2020.